Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ondansetron for Gastrointestinal Dysfunctions in Diabetes and Dyspepsia
NCT03865290Phase 2Recruiting
- Sponsor
- Mayo Clinic
- Start
- Apr 2019
- Primary completion
- Mar 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ondansetron in dyspepsia and diabetic gastroenteropathy (DG) (6 arms), sponsored by Mayo Clinic. Primary endpoints: Change in severity of symptoms during enteral infusion up to 8 hours, Change in severity of symptoms during gastric emptying study up to 2 hours and 4 more. Started Apr 2019; status: recruiting.
02
Drugs
ondansetron
03
Conditions
dyspepsiadiabetic gastroenteropathy (DG)
Beyond the preview
Go deeper on NCT03865290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03865290.